Abstract
Objective Tobacco smoking, alcohol intake, and high BMI have been identified in observational studies as potentially protective factors against developing Parkinson’s disease (PD). Because of the possibility of residual confounding and reverse causation, it is unclear whether such epidemiological associations are causal. Mendelian randomisation (MR) uses genetic variants to explore causal effects of exposures on outcomes; minimising these sources of bias. Using MR, this study sought to determine the causal relationship between tobacco smoking, alcohol intake, and high BMI, and the risk of PD.
Methods We performed genome-wide association studies to identify single nucleotide polymorphisms associated with the exposures. MR analysis of the relationship between each exposure and PD was undertaken using a split-sample design. The inverse variance weighted (IVW) method was used to combine SNP-specific effect estimates.
Results Ever-smoking causally reduced risk of PD (OR 0.955; 95% confidence interval [CI] 0.921-0.991; p=0.013). An increase in daily alcohol intake causally increased risk of PD (OR 1.125, 95% CI 1.025-1.235; p=0.013) and a 1 kg/m2 BMI causally reduced risk of PD (OR 0.988, 95% CI 0.979-0.997; p=0.008). Sensitivity analyses did not suggest bias from horizontal pleiotropy or invalid instruments.
Interpretation Using split-sample MR in over 2.4 million participants, we observed a protective effect of smoking on risk of PD, warranting the prioritisation of related therapeutic targets, such as nicotinic agonists, in prevention trials. In contrast to observational data, alcohol consumption causally increased risk of PD. Higher BMI had a protective effect on PD, but the effect was small.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Drs. Heilbron, Fontanillas, Cannon, and members of the 23andMe Research Team are employees of and have stock, stock options, or both, in 23andMe. Dr Noyce works at the Preventive Neurology Unit which is funded by the Barts Charity (reference MGU0364). Dr Noyce reports additional grants from Parkinson's UK, Virginia Kieley Benefaction, grants and non-financial support from GE Healthcare, and personal fees from Profile, Roche, Biogen, Bial and Britannia, outside the submitted work. Dr Nalls' participation in this work was supported in part by a consulting contract with the Intramural Research Program of the National Institute on Aging (NIA), Department of Health and Human Services; under project Z01-AG000949-02. Dr Nalls is also a founding partner at Data Tecnica International LLC, which during the time of this report has consulted for the National Institutes of Health (USA), the Michael J. Fox Foundation, Illumina Inc., Vivid Genomics, Lysosomal Therapeutics Inc., Neuron 23 Inc. and Aspen Biosciences among others, all of which had no impact on his participation in this work.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary statistics for both the exposure and outcome GWASes for the relevant set of exposure SNPs are available in the supplementary data.
